HAMBURG, Germany , Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics,...
Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseases Evotec brings...
Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting
D isclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
SEATTLE and HAMBURG, Germany , June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN,...
11.06.2026 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement.
HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025...
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth
HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April...